General MedicationsINTRAVENOUS, SUBCUTANEOUSStandard
TREPROSTINIL
TREPROSTINIL
Standard Dose
5MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview TREPROSTINIL is listed in Drugs@FDA under application 211574 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TREPROSTINIL Form and strength INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 5MG/ML Sponsor ALEMBIC GLOBAL Submission history Latest submission status date: 2021-02-11 00:00:00.
Structured Monograph
Clinical summary
Approval overview TREPROSTINIL is listed in Drugs@FDA under application 211574 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TREPROSTINIL Form and strength INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 5MG/ML Sponsor ALEMBIC GLOBAL Submission history Latest submission status date: 2021-02-11 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.